Perosphere Technologies to Deliver Oral Presentation & Posters on Point-of-Care Coagulometer at ADLM International CPOCT Symposium
Perosphere (Perosphere Technologies Inc.), a private medical technologies company focused on developing next-generation coagulation diagnostics, today announced its participation on the agenda of the 29th ADLM International Critical & Point of Care Testing (CPOCT) Symposium, held September 25-27, 2024 in San Diego, CA. Perosphere CEO Dr. Sasha Bakhru will deliver an oral presentation highlighting the accuracy and effectiveness of measuring the Whole Blood Clotting Time (WBCT) with the company’s novel point-of-care coagulometer, Perosphere ClotChek™, for patients on direct oral anticoagulants (DOACs) compared to normal, non-medicated individuals. An additional featured poster describes the in vitro validation of Perosphere ClotChek.
“We are thankful to ADLM for convening this symposium to highlight the latest innovations in critical and point-of-care testing,” said Sasha Bakhru, PhD, CEO of Perosphere. “We are proud to present data on our novel point-of-care coagulometer, Perosphere ClotChek, that can address a significant unmet need as designed with sensitivity for patients on DOACs at risk for bleeding.”
The details of the presentations are as follows:
Oral Presentation
Selected as one of the top research abstracts at the symposium, Dr. Bakhru will highlight results from a study characterizing the response of the Perosphere ClotChek coagulometer to DOAC-induced anticoagulation in whole blood samples from DOAC patients at peak anticoagulation and at minimal anticoagulation, with comparison to ClotChek results in normal, non-medicated subjects.
Oral Poster Presentation Title: Clinical Performance of a Novel Point-of-Care Coagulometer for the DOACs
Presenter: Sasha Bakhru, PhD, CEO, Perosphere
Presentation Date: September 26, 2024
Presentation Time: 3:15 - 3:30 pm
Dr. Bakhru will detail the observed sensitivity of Perosphere ClotChek WBCT versus other comparator measures, as well as strong linear correlation for clotting time versus drug concentration, and high precision of the instrument.
Scientific Posters on Display
Perosphere will feature two posters among the 32 total on display at the conference, including the oral presentation poster and a poster describing the evaluation of the point-of-care coagulometer for accuracy, linearity, and precision utilizing venous whole blood and liquid quality controls.
Poster Title: Accuracy and Precision Evaluation of a Novel Point-of-Care Coagulometer for the DOACs
Author: Dardan Osmani, MS, MBA, Director of Technical Operations, Perosphere
Together, the data to be presented at the ADLM International CPOCT Symposium serves to illustrate that Perosphere ClotChek, a novel point-of-care coagulometer, demonstrates encouraging performance in accurately and precisely measuring the pharmacodynamic effects of DOACs, delivering results within 3-8 minutes and requiring only a single drop of fresh whole blood from a venous blood draw.
For more information about the 29th ADLM International CPOCT Symposium, visit https://www.myadlm.org/meetings-and-events/international-cpoct-symposium.
About Perosphere Technologies
Perosphere Technologies is changing the way decisions are made at the point of care in hospitals and outpatient clinics for patients at risk for bleeding. A private medical technologies company, Perosphere is focused on development and commercialization of Perosphere ClotChekTM, a novel PoC (point-of-care) Coagulometer, which quickly informs diagnosis, treatment, and prevention decisions through precision data, made immediately accessible to all. This novel PoC diagnostic instrument effectively and swiftly measures Whole Blood Clotting Times (WBCT) with a high degree of sensitivity appropriate for several drug classes, including the Direct Oral Anticoagulants (DOACs). Perosphere ClotChek serves to help establish a new standard of care for patients on anticoagulant therapies or at risk for bleeding, and has the potential to improve efficiency, provide significant cost savings, and support better patient outcomes.
Perosphere ClotChek is CE Marked in the European Union and has not been subject to a FDA pre-market approval nor 510(k) cleared in the United States.
For further information, contact us at info@perospheretech.com or +1 (475) 218-4600.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240925027612/en/
Contacts
MEDIA CONTACT
Danny Sudwarts
FINN Partners
danny.sudwarts@finnpartners.com
929-588-2018
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EIG Acquires a 49.87% Stake in Transportadora de Gas del Perú (TgP)19.12.2025 18:42:00 CET | Press Release
EIG, through its managed investment vehicles, acquired a 49.87% equity stake in Transportadora de Gas del Perú S.A. (“TgP”) from Canada Pension Plan Investment Board today. TgP operates Peru’s principal natural gas and natural gas liquids pipelines under a long-term concession, supplying approximately 40% of the country’s power generation. “We are delighted to complete this transaction and embark on the next chapter of our partnership with TgP,” said Matt Hartman, EIG’s Global Head of Infrastructure. “Our priority is to support TgP’s operational excellence and long-term stability, delivering value for customers and stakeholders throughout Peru.” About EIG EIG is a leading institutional investor in the global energy and infrastructure sectors with $24.3 billion assets under management as of September 30, 2025. EIG specializes in private investments in energy and energy-related infrastructure on a global basis. During its 43-year history, EIG has committed over $51.7 billion to the energ
Klarna Partners With Coinbase to Add Stablecoin to Funding Mix19.12.2025 18:00:00 CET | Press Release
Klarna, the global digital bank and flexible payments provider, has partnered with Coinbase to add stablecoin funding to its broad range of traditional sources of funding, which include consumer deposits, long-term loans and short-dated commercial paper. The digital bank plans to raise short-term funding from institutional investors denominated in USDC utilizing Coinbase’s digitally native infrastructure. Adding a USDC-denominated funding source enables Klarna to access USD-like funding directly, tapping into a new pool of institutional investors. “This is an exciting first step into a new way to raise funding,” said Niclas Neglén, Chief Financial Officer, Klarna, “Stablecoin connects us to an entirely new class of institutional investors, and gives us the potential to diversify our funding sources in ways that simply weren't possible a few years ago. This is just the beginning of how digital assets can work alongside our traditional funding sources." Klarna chose Coinbase for this ini
CyberArk Named a Leader in IDC MarketScape: Worldwide Integrated Solutions for Identity Security 202519.12.2025 17:00:00 CET | Press Release
CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced that it has been recognized as a Leader in the IDC MarketScape: Worldwide Integrated Solutions for Identity Security 2025 Vendor Assessment. CyberArk extends dynamic privilege controls across all identity types with its unified platform, enabling organizations to improve efficiencies and streamline security operations. This IDC MarketScape report notes, “More change has occurred in the identity security marketplace in the past two years than in almost a decade. Vendors are entering a new phase defined by the emergence of intelligence technologies, none of which are specifically defined by any industry standards. Though different by design, the new adjacent IAM offerings are largely focused on improved vulnerability and threat management visibility and automated and predictive attack detection capabilities.” It also notes, “By addressing these evolving identity types within a unified framework, CyberArk enh
New York Liberty and Ant International’s Alipay+ Announce Multiyear Partnership Focused on Empowerment, Sustainability and Youth Development19.12.2025 14:30:00 CET | Press Release
The New York Liberty and Ant International’s Alipay+, a leading cross-border fintech services platform based in Singapore, today announced a multiyear partnership, making Alipay+ an Official Sponsor and Innovation Partner for Sustainability of the New York Liberty. Through this partnership, Alipay+ and the Liberty will jointly support community programs designed to advance community empowerment, environmental sustainability and youth development across New York City. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219678825/en/ Peng Yang, CEO, Ant International and Clara Wu Tsai, Vice Chair, Brooklyn Sports and Entertainment; Governor, New York Liberty “Our partnership with Alipay+ goes beyond the game,” said Keia Clarke, Chief Executive Officer, New York Liberty. “Together, we are investing in the future of New York—its people, its environment, and its youth. Ant International’s commitment to community empowerment, sustai
Parse Biosciences and Codebreaker Labs Partner to Apply Whole Transcriptome Single Cell Profiling and Causal Genomics at Scale19.12.2025 14:00:00 CET | Press Release
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a collaboration with Codebreaker Labs to develop and validate a breakthrough platform capable of testing thousands of genetic variants in parallel and measuring their effects at single cell resolution. By combining Codebreaker’s synthetic biology platform and variant engineering capabilities with the scale and accessibility of Parse’s Evercode™ technology, the collaboration aims to generate the causal data increasingly sought by AI developers, drug discovery teams, and clinical researchers. Today’s genomic studies rely heavily on observational data, or variants that appear in large populations. But rare and private variants, often only seen in one individual or family, are nearly impossible to study this way because too few carriers of the variant exist to draw statistically meaningful conclusions. As a result, even the most advanced models trained on observational datas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom